IL2 and neoplasm: Previous studies have demonstrated the ability of cetuximab to induce ADCC in various tumour types.17,32,33 Furthermore, inhibition of anti-inflammatory cytokines, such as TGF-β, or addition of pro-inflammatory cytokines, such as IL-2 and IL-15, enhanced cetuximab-mediated ADCC.34 However, knowledge regarding the effect of cetuximab sensitivity and/or HPV status on ADCC activity remains scarce.